Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2)

Warm autoimmune haemolytic anaemia is a rare blood disorder characterised by haemolysis, anaemia, elevated thromboembolism risk, fatigue, and impaired quality of life. The selective Bruton tyrosine kinase inhibitor, rilzabrutinib, might increase haemoglobin through multi-immune modulatory mechanisms targeting key drivers of warm autoimmune haemolytic anaemia pathophysiology. The aim of the study was to report clinical safety and activity results for rilzabrutinib in patients with warm autoimmune haemolytic anaemia.